 This was a multicenter, Phase 1, standard 33 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia CLL, prolymphocytic leukemia PLL or Small Lymphocytic Lymphoma SLL. 